Promising effect of PDL1 inhibitors in the front-line management of primary aggressive central nervous system lymphoma: A case report

El-Tawab, Rasha; Hamada, Abdulaziz; Elhagracy, Rehab S; Pinto, Karen; Alshemmari, Salem

doi:10.1016/j.hemonc.2020.06.003

Cited by 5 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACAs are described in all AMLs and occur in approximately onethird of patients with APL (5). The most frequent ACAs in APL are trisomy 8, isoderivative chromosome 17, abnormalities of the long arm of chromosome 7, and trisomy 21 (6). Here we present a case of APL with a novel ACA involving chromosomes 7 and 12 resulting in an out-of-frame fusion between EXOC4 and TRHDE.…”

Section: Discussionmentioning

confidence: 93%

“…Poire et al (19) reported that ACAs or CKs were associated with more relapses and significantly poorer survival in patients receiving chemotherapy-or ATO-based consolidation schedules. Additional studies reported that patients with t(15;17) alone were more sensitive to ATRA and had significantly better overall and disease-free survival compared with patients with ACAs, even in the absence of ATO (5,6). Conversely, however, Labrador et al (20) and De Botton et al (21) reported that ACAs did not affect the prognosis of APL patients with t(15;17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Co-existence of a novel EXOC4‐TRHDE gene fusion with PML-RARA in acute promyelocytic leukemia

Liu

Xiao

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is a type of myeloid leukemia with a specific chromosomal translocation t(15;17)(q22; q12) forming the PML-RARA fusion gene. However, approximately one third of newly diagnosed patients with APL have additional chromosomal abnormalities. Here, we report a case of APL with co-existence of a novel translocation t(7;12)(q32;q13) involving an out-of-frame fusion between EXOC4 and TRHDE, together with PML-RARA. The patient achieved complete remission after treatment with conventional therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Although the causative link between EXOC4‐TRHDE and PML-RARA has yet to be established, the patient had a good response to therapy, suggesting that the EXOC4‐TRHDE fusion does not affect the efficacy of combined treatment with ATRA and ATO.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Case Report: Co-existence of a novel EXOC4‐TRHDE gene fusion with PML-RARA in acute promyelocytic leukemia

Liu

Xiao

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Another case report showed that a PCNSL patient with a very poor performance status (ECOG 4) achieved MRI almost CR and regained consciousness after six cycles of 3 mg/kg single-agent nivolumab administration. 77 Nivolumab combined with lenalidomide exhibited good tolerance and antitumor activity as salvage therapy in a patient with sanctuary site CNS DLBCL, 78 whose MRI showed near CR after 2 months of the combination treatment. A multicenter phase II trial of nivolumab for the treatment of r/r PCNSL and PTL has recently been completed (NCT02857426).…”

Section: Novel Therapies For Pcnslmentioning

confidence: 99%

“… 79 In addition to being used as salvage and maintenance therapy, nivolumab monotherapy in the front-line treatment of PCNSL has shown promising effects in one PCNSL patient with poor tolerance for induction chemotherapy. 77 …”

Section: Novel Therapies For Pcnslmentioning

confidence: 99%

Novel insights into the biomarkers and therapies for primary central nervous system lymphoma

2022

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive extranodal type of non-Hodgkin lymphoma. After the introduction and widespread use of high-dose-methotrexate (HD-MTX)-based polychemotherapy, treatment responses of PCNSL have been improved. However, long-term prognosis for patients who have failed first-line therapy and relapsed remains poor. Less invasive diagnostic markers, including the circulating tumor DNAs (ctDNAs), microRNAs, metabolomic markers, and other novel biomarkers, such as a proliferation inducing ligand (APRIL) and B-cell activating factor of the TNF family (BAFF), have shown potential to distinguish PCNSL at an early stage, and some of them are related with prognosis to a certain extent. Recent insights into novel therapies, including Bruton tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, PI3K/mTOR inhibitors, and chimeric antigen receptor (CAR) T cells, have revealed encouraging efficacy in treatment response, whereas the duration of response and long-term survival of patients with relapsed or refractory PCNSL (r/r PCNSL) need further improvement. In addition, the diagnostic efficiency of novel markers and the antitumor efficacy of novel therapies are needed to be assessed further in larger clinical trials. This review provides an overview of recent research on novel diagnostic markers and therapeutic strategies for PCNSL.

show abstract

“…Most data available at this time for the use of ICIs in PCNSL come from case reports and small retrospective case series (see Table 4 ). However, among these are encouraging results, such as a case report demonstrating complete remission and clinical amelioration in a patient with poor performance status [ 73 ]. A more informed perspective on ICI use in this type of tumor will emerge from the ongoing studies listed in Table 4 .…”

Section: Ici For Primary Brain Tumorsmentioning

confidence: 99%

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors

Alimonti

Castro

2023

Antibodies

View full text Add to dashboard Cite

Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the available evidence for the use of ICIs in the treatment of primary and metastatic brain tumors, highlighting challenges and opportunities for furthering this type of cancer immunotherapy in neuro-oncology.

show abstract

Promising effect of PDL1 inhibitors in the front-line management of primary aggressive central nervous system lymphoma: A case report

Cited by 5 publications

References 4 publications

Case Report: Co-existence of a novel EXOC4‐TRHDE gene fusion with PML-RARA in acute promyelocytic leukemia

Case Report: Co-existence of a novel EXOC4‐TRHDE gene fusion with PML-RARA in acute promyelocytic leukemia

Novel insights into the biomarkers and therapies for primary central nervous system lymphoma

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors

Contact Info

Product

Resources

About